Introduction In clinical studies evaluating therapies for major diseases such as cancer, overall survival (OS) is a gold standard endpoint. Yet OS blends multiple failure causes and can obscure the actual burden of disease- or treatment-related events. In long follow-ups, competing risks (e.g., non-disease death) influence observed outcomes and make crude cumulative incidence (CIF) a…